Neogen Corporation logo

Neogen Corporation

NEOG

NASDAQHealthcareMedical - Devices

Previous close

$11.95

+$0.12 · +1.01%

Aug 21, 4:00 PM ET

NEOG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

57

Neutral

Sentiment

53

Mixed

Risk resilience

52

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Mikhael Nassif
Listed since
Aug 23, 1989
Employees
2,636

Market position

Day range

Current $11.95

52-week range

Current $11.95

Open
$11.885
Previous close
$11.83
Volume
1.21M
0.54× average
Average volume
2.23M
Average daily volume
Market cap
2.61B USD
Beta
1.77
Market reference 1
50-day average
$10.2162
+16.97% above average
200-day average
$9.095
+31.39% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.55B USD
EV / EBITDA
14.95×
Earnings yield
-0.41%
Free cash flow yield
1.64%

Profitability & efficiency

Return on equity
-0.38%
Return on assets
-0.24%
Return on invested capital
-0.59%

Financial health

Current ratio
3.82×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends67%-2%-70%-139%Gross margin, FY2022: 46.10%Gross margin, FY2023: 49.36%Gross margin, FY2024: 50.06%Gross margin, FY2025: 47.10%Gross margin, FY2026: 46.93%Operating margin, FY2022: 11.12%Operating margin, FY2023: 4.56%Operating margin, FY2024: 8.38%Operating margin, FY2025: 1.05%Operating margin, FY2026: -2.48%Net margin, FY2022: 9.16%Net margin, FY2023: -2.78%Net margin, FY2024: -1.02%Net margin, FY2025: -122.06%Net margin, FY2026: -0.91%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 46.10%. Gross margin FY2023 49.36%. Gross margin FY2024 50.06%. Gross margin FY2025 47.10%. Gross margin FY2026 46.93%. Operating margin FY2022 11.12%. Operating margin FY2023 4.56%. Operating margin FY2024 8.38%. Operating margin FY2025 1.05%. Operating margin FY2026 -2.48%. Net margin FY2022 9.16%. Net margin FY2023 -2.78%. Net margin FY2024 -1.02%. Net margin FY2025 -122.06%. Net margin FY2026 -0.91%.

Income trends

Revenue

870.4M USD-2.71%

Operating income

−21.6M USD−31.02M USD

Net income

−7.9M USD+99.28%
Income trends across reported periods1.13B USD319.34M USD−487.16M USD−1.29B USDRevenue, FY2022: 527.16M USDRevenue, FY2023: 822.45M USDRevenue, FY2024: 924.22M USDRevenue, FY2025: 894.66M USDRevenue, FY2026: 870.4M USDOperating income, FY2022: 58.62M USDOperating income, FY2023: 37.52M USDOperating income, FY2024: 77.43M USDOperating income, FY2025: 9.42M USDOperating income, FY2026: −21.6M USDNet income, FY2022: 48.31M USDNet income, FY2023: −22.87M USDNet income, FY2024: −9.42M USDNet income, FY2025: −1.09B USDNet income, FY2026: −7.9M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 527.16M USD. Revenue FY2023 822.45M USD. Revenue FY2024 924.22M USD. Revenue FY2025 894.66M USD. Revenue FY2026 870.4M USD. Operating income FY2022 58.62M USD. Operating income FY2023 37.52M USD. Operating income FY2024 77.43M USD. Operating income FY2025 9.42M USD. Operating income FY2026 −21.6M USD. Net income FY2022 48.31M USD. Net income FY2023 −22.87M USD. Net income FY2024 −9.42M USD. Net income FY2025 −1.09B USD. Net income FY2026 −7.9M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue870.4M USD894.66M USD924.22M USD822.45M USD527.16M USD
Cost of goods sold461.9M USD473.29M USD461.59M USD416.49M USD284.15M USD
Gross profit408.5M USD421.38M USD462.64M USD405.96M USD243.01M USD
Research and development18.4M USD21.09M USD22.48M USD26.04M USD17.05M USD
Selling, general, and administrative411.7M USD401.97M USD382.76M USD342.4M USD167.35M USD
Operating expenses430.1M USD411.96M USD385.21M USD368.44M USD184.4M USD
Interest income3.11M USD6.36M USD3.17M USD1.34M USD
Interest expense57.6M USD71.62M USD73.39M USD55.96M USD72K USD
Depreciation and amortization121.9M USD125.67M USD121.23M USD88.38M USD23.69M USD
Operating income−21.6M USD9.42M USD77.43M USD37.52M USD58.62M USD
Net income−7.9M USD−1.09B USD−9.42M USD−22.87M USD48.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-535.52%
11 comparable reports
Latest EPS result
0.09
Estimate 0.06 · Beat by 58.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.37-0.77-1.92-3.06Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual -2.1, estimate 0.09, surprise -2433.33%, Miss. Q2 2025, reported Apr 9, 2025: actual -0.05, estimate 0.13, surprise -138.46%, Miss. Q3 2025, reported Jul 28, 2025: actual -2.82, estimate 0.08, surprise -3625.00%, Miss. Q4 2025, reported Oct 9, 2025: actual 0.04, estimate -0.074, surprise +154.05%, Beat. Q1 2026, reported Jan 8, 2026: actual 0.1, estimate 0.07, surprise +42.86%, Beat. Q2 2026, reported Apr 9, 2026: actual 0.09, estimate 0.04, surprise +125.00%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.09, estimate 0.057, surprise +58.81%, Beat. Q4 2026, reported Oct 8, 2026: actual —, estimate 0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates240.55M224.98M209.41M193.84MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual 231.3M USD, estimate 228.33M USD, surprise +1.30%, Beat. Q2 2025, reported Apr 9, 2025: actual 220.98M USD, estimate 224.1M USD, surprise -1.39%, Miss. Q3 2025, reported Jul 28, 2025: actual 225.46M USD, estimate 221.93M USD, surprise +1.59%, Beat. Q4 2025, reported Oct 9, 2025: actual 209.2M USD, estimate 203.09M USD, surprise +3.01%, Beat. Q1 2026, reported Jan 8, 2026: actual 224.69M USD, estimate 207.71M USD, surprise +8.18%, Beat. Q2 2026, reported Apr 9, 2026: actual 211.2M USD, estimate 204.49M USD, surprise +3.28%, Beat. Q3 2026, reported Jul 30, 2026: actual 225.3M USD, estimate 212.35M USD, surprise +6.10%, Beat. Q4 2026, reported Oct 8, 2026: actual —, estimate 207.9M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$13.00

8.79% upside
Past 12 months12-month forecastHigh $13.00Average $13.00Low $13.00

Rating distribution

11 ratings
Strong buy00%
Buy436%
Hold655%
Sell19%
Strong sell00%

NEOG news

NEOG peers

ETFs holding NEOG

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research NEOG

research.disclaimer